Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 1/20 | 0.39 |
| ▸ | SLC6A12 | P48065 | 3/20 | 0.35 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.35 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | GRM6 | O15303 | 2/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.30 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19816446 | 1.00 | GABRR1 (0.39) | GABRR1SLC6A12SLC6A11SLC6A13CHRNA7 | |
| SCHEMBL3620778 | 1.00 | GABRR1 (0.39) | GABRR1SLC6A12SLC6A11SLC6A13CHRNA7 | |
| SCHEMBL4627762 | 1.00 | GABRR1 (0.39) | GABRR1SLC6A12SLC6A11SLC6A13CHRNA7 | |
| SCHEMBL3832575 | 1.00 | GABRR1 (0.39) | GABRR1SLC6A12SLC6A11SLC6A13CHRNA7 | |
| SCHEMBL18957048 | 0.85 | GABRR1 (0.33) | GABRR1SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL841973 | 0.85 | GABRR1 (0.33) | GABRR1SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL4609252 | 0.85 | GABRR1 (0.33) | GABRR1SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL505726 | 0.85 | GABRR1 (0.33) | GABRR1SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL18555595 | 0.85 | GABRR1 (0.33) | GABRR1SLC6A12SLC6A11SLC6A13 | |
| SCHEMBL5403763 | 0.85 | GABRR1 (0.33) | GABRR1SLC6A12SLC6A11SLC6A13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11926613-B2 | Kinase inhibitors for the treatment of central and peripheral nervous system disorders | UNIVERSITY OF MIAMI (US) | 2024-03-12 | — | — | US | disclosed |
| US-20230140395-A1 | NOVEL IMIDAZOLE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2023-05-04 | — | — | US | disclosed |
| US-20210163444-A1 | KINASE INHIBITORS FOR THE TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS | UNIVERSITY OF MIAMI | 2021-06-03 | — | — | US | disclosed |
| CN-111801322-A | Kinase inhibitors for the treatment of central and peripheral nervous system disorders | 迈阿密大学 | 2020-10-20 | — | — | CN | disclosed |
| EP-3704103-A1 | KINASE INHIBITORS FOR THE TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS | University of Miami (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-1978804-B1 | AMINOCYCLOHEXANES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME (US) | 2014-07-30 | — | — | EP | disclosed |
| US-7750034-B2 | Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090270467-A1 | Aminocyclohexanes as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK & CO., INC. (US) | 2009-10-29 | — | — | US | disclosed |
| EP-1978804-A2 | AMINOCYCLOHEXANES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007087231-A2 | AMINOCYCLOHEXANES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270467-A1 | Aminocyclohexanes as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | GABRR1 4387/4885SLC6A12 2180/4885SLC6A11 2144/4885 |
| US-20210163444-A1 | KINASE INHIBITORS FOR THE TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS | PNCK, PYGB, PMP22 | GABRR1 376/4885SLC6A12 3150/4885SLC6A11 1099/4885 |
| US-11926613-B2 | Kinase inhibitors for the treatment of central and peripheral nervous system disorders | PNCK, PYGB, PMP22 | GABRR1 376/4885SLC6A12 3150/4885SLC6A11 1099/4885 |
| US-20230140395-A1 | NOVEL IMIDAZOLE DERIVATIVE HAVING PROTEIN KINASE INHIBITORY ACTIVITY, AND USE THEREOF | MAPKAPK3, MAPK3, MAP3K3 | GABRR1 1792/4885SLC6A12 4197/4885SLC6A11 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.